Upstream & downstream
Fermentation and downstream processing take place in separate facilities equipped for protein purification.
Fermentation & GMP production
BBT Biotech specialises in fermentation, protein purification and GMP production of biological active ingredients.
BBT Biotech develops and manufactures biopharmaceutical active ingredients with a focus on fermentation and protein purification.
BBT Biotech specialises in contract development and GMP manufacture of biopharmaceutical active ingredients. Fermentation, purification and analytical assurance are closely integrated.
Fermentation and downstream processing take place in separate facilities equipped for protein purification.
Comprehensive in-house quality control and regulatory documentation.
Capabilities
Six core capabilities form the foundation of specialised CDMO services.
Scalable cultivation of microorganisms and proteins under controlled process conditions.
Purification of proteins and biomolecules for pharmaceutical applications.
Media preparation, inoculum development and controlled process management.
Chromatography and filtration as parts of downstream processing.
Authorised production under applicable EU GMP requirements for biopharmaceutical active ingredients.
Comprehensive in-house analytics and support for regulatory documentation.
Active ingredient portfolio
Selected BBT Biotech active ingredients from the thrombolytics, inhibitors, enzymes, probiotics and postbiotics portfolio.
BBT Biotech's principal product: highly purified urokinase manufactured under GMP conditions in accordance with the European and Japanese Pharmacopoeia monographs.
BBT Biotech manufactures highly purified streptokinase under GMP conditions in accordance with the European Pharmacopoeia monograph.
BBT Biotech offers aprotinin as a broad-spectrum protease inhibitor manufactured under GMP conditions. The active ingredient is available as a frozen solution or powder.
BBT Biotech manufactures hyaluronidase of natural origin under GMP conditions in accordance with the requirements of the European Pharmacopoeia monograph.
BBT Biotech's portfolio includes the two non-pathogenic E. coli strains Nissle 1917 and K12. BBT offers them as highly viable concentrates or inactivated postbiotics manufactured under GMP conditions.
Explore its fermentation, purification and GMP manufacturing capabilities for biological active ingredients.